MNOV vs MOLN

MediciNova, Inc. vs Molecular Partners AG — Valuation Comparison 2026

By CirclFi Research Team · Updated 2026-06-03 · Data from SEC EDGAR, FRED & GDELT

Quick Summary — MNOV scores higher on quality with 6.2/10 vs MOLN's 4.7/10. MNOV trades at $1.34 while MOLN trades at $3.92. Both analyzed daily using SEC EDGAR data across 13 institutional models.

MNOV

Biotechnology
MediciNova, Inc.
Quality
6.2
out of 10
Value Trap
45
WARN
Price
$1.34
Last close
Models
9/13
Active
VS

MOLN

Biotechnology
Molecular Partners AG
Quality
4.7
out of 10
Value Trap
26
LOW
Price
$3.92
Last close
Models
8/13
Active
MNOV
2 models active
Value Trap 45/100 — caution
MOLN
2 models active
Quality 4.7/10 — below average

MNOV vs MOLN — Fair Value Comparison

MNOV
$0$1$1$2 Price$1.34 Bayesian …$0.66 (-51.1%) Dynamic N…$1.33 (-1.0%)
MOLN
$0$2$3$5 Price$3.92 Bayesian …$1.16 (-70.4%) Dynamic N…$1.69 (-56.9%)
Market Price Model 1 Model 2

Model-by-Model Comparison

ModelType MNOV Fair ValueMNOV Upside MOLN Fair ValueMOLN Upside
Bayesian DCF Intrinsic $0.66 -51.1% $1.16 -70.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.33 -1.0% $1.69 -56.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%

MNOV vs MOLN — Which Stock Is More Undervalued in 2026?

MNOV scores higher with a 6.2/10 quality rating vs MOLN's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do MNOV and MOLN Valuations Compare?

At $1.34, MNOV trades +51.1% above its Bayesian DCF fair value of $0.66, while MOLN at $3.92 trades +70.4% above its estimate of $1.16. MOLN shows a wider gap between price and intrinsic value.

Quality of Company: MNOV vs MOLN

MNOV earns a Quality of Company score of 6.2/10 compared to MOLN's 4.7/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: MNOV vs MOLN

MNOV carries a WARN value trap risk (45/100) while MOLN shows LOW risk (26/100). Stocks with value trap scores above 40 may appear undervalued but face deteriorating fundamentals — declining margins, rising debt, or shrinking revenue can make the apparent discount a trap.

Both in Biotechnology

Both MNOV and MOLN operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare MNOV vs MOLN differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo  ·  FactSet: ~$1,000/mo  ·  CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

MNOV
View Full MediciNova, Inc. Analysis →
MOLN
View Full Molecular Partners AG Analysis →
See all Biotechnology stocks →